AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31419353 — intervention group
Group type: COMPARATOR
Intervention: Passive treatment group (PTG, n = 13)
Number of subjects: 26
Study 30635159 — intervention group
Group type: EXPERIMENTAL
Intervention: SBC-103 (5.0 mg/kg)
Number of subjects: 11
Study 30635159 — intervention group
Group type: EXPERIMENTAL
Intervention: SBC-103 (10.0 mg/kg)
Number of subjects: 11
Study 28456800 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 856
Study 28456800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 856
Study 25666315 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 149
Study 25666315 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 149
Study 23640009 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch alone (control condition)
Number of subjects: 606
Study 23640009 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion augmentation of the patch
Number of subjects: 606
Study 23640009 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline alone
Number of subjects: 606
Study 21832964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sea buckthorn oil (2 g daily for 3 months)
Number of subjects: 100
Study 21832964 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil (2 g daily for 3 months)
Number of subjects: 100
Study 19358501 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy
Number of subjects: 66
Study 19358501 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 66
Study 16989377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry mopping and boric acid in alcohol ear drops
Number of subjects: 328
Study 16989377 — intervention group
Group type: COMPARATOR
Intervention: Dry mopping alone
Number of subjects: 328
Study 16989377 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin added to treatment
Number of subjects: 328
Study 16989377 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing test before and after treatment
Number of subjects: 328
Study 16989377 — intervention group
Group type: EXPERIMENTAL
Intervention: Boric acid in alcohol ear drops
Number of subjects: 328
Study 12710223 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual triangulation using crossed hand-held rods
Number of subjects: 24
Study 12813265 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 39
Study 12813265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9193323 — intervention group
Group type: EXPERIMENTAL
Intervention: DZR (DZR-to-doxorubicin ratio, 10:1)
Number of subjects: 534
Study 9193323 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 534
Study 1447641 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein hydrolysate formula
Number of subjects: 177
Study 1447641 — intervention group
Group type: COMPARATOR
Intervention: Adapted cow milk formula (Control)
Number of subjects: 177
Study 3485757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3485757 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg X d‐1)
Number of subjects: 0
Study 3485757 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg X d‐1)
Number of subjects: 0
Study 3485757 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 31410672 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP with diode laser (940 nm)
Number of subjects: 21
Study 31410672 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP with photodynamic therapy (670 nm)
Number of subjects: 21
Study 31410672 — intervention group
Group type: COMPARATOR
Intervention: SRP alone (control group)
Number of subjects: 21
Study 27142209 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic totally extraperitoneal (SP TEP)
Number of subjects: 99
Study 27142209 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic totally extraperitoneal (CL TEP)
Number of subjects: 99
Study 24158978 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm ergometry, rowing, bicycle ergometry for 8-10 weeks
Number of subjects: 42
Study 24158978 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 42
Study 22752384 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK1521498 5 mg/day
Number of subjects: 0
Study 22752384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20220282 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (40 min, once a day for 8 days)
Number of subjects: 60
Study 20220282 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 60
Study 19099160 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Number of subjects: 31
Study 19099160 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study 14677069 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P (power athletes)
Number of subjects: 12
Study 14677069 — intervention group
Group type: COMPARATOR
Intervention: Group E (endurance athletes)
Number of subjects: 12
Study 11390728 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g oral administration)
Number of subjects: 13
Study 11390728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9232130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phenylephrine, 50‐200 micrograms/min, titrated to a 20% increase in mean arterial blood pressure
Number of subjects: 12
Study 9232130 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO), 40 ppm
Number of subjects: 12
Study 9232130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of phenylephrine and NO
Number of subjects: 12
Study 8355067 — intervention group
Group type: EXPERIMENTAL
Intervention: Technetium-99m tetrofosmin
Number of subjects: 26
Study 8355067 — intervention group
Group type: COMPARATOR
Intervention: 201Tl
Number of subjects: 26
Study 2901302 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg oral pyridostigmine
Number of subjects: 6
Study 2901302 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms i.v. GHRH (1‐29) NH2
Number of subjects: 6
Study 2901302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine and methionyl‐hGH
Number of subjects: 6
Study 2901302 — intervention group
Group type: COMPARATOR
Intervention: Methionyl‐hGH
Number of subjects: 6
Study 30120476 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA testing followed by invasive testing only if cfDNA results are positive (n=1034)
Number of subjects: 2111
Study 30120476 — intervention group
Group type: COMPARATOR
Intervention: Immediate invasive testing procedures (n=1017)
Number of subjects: 2111
Study 30120476 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA testing
Number of subjects: 2111
Study 26810442 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy‐dense formula (Calogen Extra, Nutricia) 30 mL distributed 3 times daily for 6 weeks
Number of subjects: 28
Study 25262378 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs' micrographic surgery (MMS)
Number of subjects: 612
Study 25262378 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision (SE)
Number of subjects: 612
Study 23391814 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT + SRS
Number of subjects: 126
Study 23391814 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT + SRS + TMZ (75 mg/m(2)/day × 21 days)
Number of subjects: 126
Study 23391814 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT + SRS + ETN (150 mg/day)
Number of subjects: 126
Study 23391814 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT + SRS + TMZ
Number of subjects: 126
Study 23391814 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT + SRS + ETN
Number of subjects: 126
Study 21211299 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 40
Study 21211299 — intervention group
Group type: COMPARATOR
Intervention: 0.9% Sodium Chloride
Number of subjects: 40
Study 18981888 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) plus conventional medical management (CMM)
Number of subjects: 100
Study 18981888 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management (CMM)
Number of subjects: 100
Study 18981888 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) as final treatment
Number of subjects: 100
Study 18981888 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management (CMM) as final treatment
Number of subjects: 100
Study 18981888 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 100
Study 16622435 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel-cisplatin (docetaxel 85 mg m-2 on day 1, cisplatin 40 or 50 mg m-2 on days 1 and 2 for three 3-week cycles)
Number of subjects: 75
Study 16622435 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel-cisplatin
Number of subjects: 75
Study 12594153 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 10 mg mixed with sodium bicarbonate 8.4% 2 ml
Number of subjects: 250
Study 12594153 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 10 mg mixed with fentanyl 100 micro g
Number of subjects: 250
Study 12594153 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 10 mg mixed with lidocaine 2%
Number of subjects: 250
Study 12594153 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 10 mg mixed with normal saline
Number of subjects: 250
Study 12594153 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 10 mg alone
Number of subjects: 250
Study 10988281 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8 to 16 mg once daily)
Number of subjects: 216
Study 10988281 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (continued)
Number of subjects: 216
Study 10988281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (withdrawal of candesartan)
Number of subjects: 216
Study 9238898 — intervention group
Group type: EXPERIMENTAL
Intervention: SofScale scaling gel
Number of subjects: 0
Study 9238898 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (conventional toothpaste)
Number of subjects: 0
Study 9238898 — intervention group
Group type: COMPARATOR
Intervention: Non-treated calculus
Number of subjects: 0
Study 1452799 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol hydrochloride mouthrinse
Number of subjects: 12
Study 1452799 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine rinse
Number of subjects: 12
Study 1452799 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 12
Study 2409850 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ketotifen orally
Number of subjects: 16
Study 2409850 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 16
Study 31539293 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training combined with Virtual Reality (VR) for 12 weeks
Number of subjects: 40
Study 31539293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical effort or intervention)
Number of subjects: 40
Study 30523133 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down therapy
Number of subjects: 400
Study 30523133 — intervention group
Group type: COMPARATOR
Intervention: Accelerated step-up therapy
Number of subjects: 400
Study 26260754 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume PEG plus ascorbic acid (LV-PEG+Asc)
Number of subjects: 319
Study 26260754 — intervention group
Group type: COMPARATOR
Intervention: Split dose of polyethylene glycol (SD-PEG)
Number of subjects: 319
Study 24798668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length measurement < 30 mm
Number of subjects: 507
Study 24798668 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model including cervical length and other predictors
Number of subjects: 507
Study 24798668 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous preterm delivery, monochorionicity, smoking, educational level, triplet pregnancy
Number of subjects: 507
Study 22282264 — intervention group
Group type: EXPERIMENTAL
Intervention: New generic formulation of entecavir tablets (test)
Number of subjects: 0
Study 22282264 — intervention group
Group type: COMPARATOR
Intervention: Available branded formulation of entecavir tablets (reference)
Number of subjects: 0
Study 22282264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference formulations
Number of subjects: 0
Study 21171314 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated postoperative radiotherapy (CB)
Number of subjects: 112
Study 21171314 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative radiotherapy (C)
Number of subjects: 112
Study 17187655 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin transdermal system (OXY‐TDS) 3.9 mg/day for </=6 months
Number of subjects: 2878
Study 15292314 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (30 mg/d)
Number of subjects: 40
Study 11133904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol (approximately 3 mg/day)
Number of subjects: 8
Study 11133904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9610700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg daily for either 2 or 5 years)
Number of subjects: 432
Study 9610700 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 432
Study 7869462 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive parental relationships
Number of subjects: 479
Study 7869462 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental substance use problems (SUPs)
Number of subjects: 479
Study 7869462 — intervention group
Group type: EXPERIMENTAL
Intervention: Males reporting positive parental relationships and no parental SUPs
Number of subjects: 479
Study 3347651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic stretching
Number of subjects: 43
Study 3347651 — intervention group
Group type: COMPARATOR
Intervention: Sustained stretching
Number of subjects: 43
Study 29351791 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical acupuncture
Number of subjects: 120
Study 29351791 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 120
Study 27676662 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 0.5% (3 mL) + Methylprednisolone (40 mg) + Saline (1 mL)
Number of subjects: 33
Study 27676662 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5% (3 mL) + Methylprednisolone (40 mg) + Calcitonin (50 IU)
Number of subjects: 33
Study 27676662 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Lidocaine + Methylprednisolone + Saline vs. Calcitonin)
Number of subjects: 33
Study 25078304 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once daily plus asunaprevir 100 mg twice daily for 12 weeks
Number of subjects: 307
Study 25078304 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once daily plus asunaprevir 100 mg twice daily for 24 weeks
Number of subjects: 307
Study 25078304 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 307
Study 23522987 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfractures of the greater tuberosity during arthroscopic rotator cuff repair (Group 2)
Number of subjects: 80
Study 23522987 — intervention group
Group type: COMPARATOR
Intervention: Standard repair (Group 1)
Number of subjects: 80
Study 23522987 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfractures of the greater tuberosity (Group 2) for large tears
Number of subjects: 80
Study 23522987 — intervention group
Group type: COMPARATOR
Intervention: Standard repair (Group 1) for large tears
Number of subjects: 80
Study 20540803 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous informed consent process using locally-appropriate pictorial flipchart and pre-recorded audio tapes
Number of subjects: 1146
Study 20540803 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous informed consent process
Number of subjects: 1146
Study 18391475 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (10 g/d, ALA intake 5.5 g/d)
Number of subjects: 42
Study 18391475 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (placebo, 10 g/d)
Number of subjects: 42
Study 16636028 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesiologist-controlled sedation (ACS)
Number of subjects: 64
Study 16636028 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled sedation (PCS)
Number of subjects: 64
Study 14673725 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 600 mg daily for 6 months
Number of subjects: 106
Study 14673725 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UDCA)
Number of subjects: 106
Study 15532695 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic medicine (Cantharis 30c)
Number of subjects: 11
Study 15532695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10347395 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (group nutrition education classes)
Number of subjects: 502
Study 10347395 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (individual self-paced nutrition education program)
Number of subjects: 502
Study 10347395 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (control group receiving usual nutrition education)
Number of subjects: 502
Study 7498042 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezoidal flap (TF)
Number of subjects: 20
Study 7498042 — intervention group
Group type: COMPARATOR
Intervention: Semilunar flap (SF)
Number of subjects: 20
Study 1712524 — intervention group
Group type: EXPERIMENTAL
Intervention: ERU capsules (Radicis urticae) for 7 days
Number of subjects: 2
Study 1712524 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 2
Study 7002338 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 5656 rads in 28 fractions in 5 1/2 weeks (202 rads daily)
Number of subjects: 55
Study 7002338 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: 4352 rads in 12 unequal fractions in 4 weeks (294 rads each Monday and Wednesday and 500 rads on Fridays)
Number of subjects: 55
Study 7002338 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: 4352 rads in 12 unequal fractions in 4 weeks with 3 g/m2 oral misonidazole 4 hours before the 500-rad fraction, once a week for 4 weeks
Number of subjects: 55
Study 31578113 — intervention group
Group type: EXPERIMENTAL
Intervention: Early video capsule
Number of subjects: 87
Study 31578113 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 87
Study 28921841 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein restriction (PR) for one month
Number of subjects: 0
Study 28921841 — intervention group
Group type: COMPARATOR
Intervention: Control diet for one month
Number of subjects: 0
Study 25860126 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (20 µg to 140 µg, adjusted based on previous patient's response)
Number of subjects: 40
Study 25860126 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (140 µg)
Number of subjects: 40
Study 25860126 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (not specified)
Number of subjects: 40
Study 24054343 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomic regulation therapy (ART)
Number of subjects: 0
Study 24054343 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation
Number of subjects: 0
Study 24054343 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 21377144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for insomnia for AD (CBTI-AD, n=9)
Number of subjects: 17
Study 21377144 — intervention group
Group type: COMPARATOR
Intervention: Behavioral placebo treatment (BPT, n=8)
Number of subjects: 17
Study 19614786 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 2.5 mg
Number of subjects: 768
Study 19614786 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Number of subjects: 768
Study 19614786 — intervention group
Group type: COMPARATOR
Intervention: Uptitrated glyburide (10 mg to 15 mg)
Number of subjects: 768
Study 16763053 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic gastroplication
Number of subjects: 60
Study 16763053 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 60
Study 16763053 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 60
Study 15285300 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive information leaflet and reminder letters
Number of subjects: 500
Study 15285300 — intervention group
Group type: COMPARATOR
Intervention: Standard basic information
Number of subjects: 500
Study 11336663 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9624484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 84
Study 9624484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-vancomycin
Number of subjects: 84
Study 8080747 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy response (complete response, partial response, stable disease)
Number of subjects: 324
Study 2975491 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of HBV vaccine (5 micrograms)
Number of subjects: 40
Study 2975491 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose of HBV vaccine (2 micrograms)
Number of subjects: 40
Study 30921795 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks of spa therapy (group 1)
Number of subjects: 60
Study 30921795 — intervention group
Group type: COMPARATOR
Intervention: 2 weeks of spa therapy (group 2)
Number of subjects: 60
Study 27359182 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD-delivered exercise intervention (FlexToBa)
Number of subjects: 307
Study 27359182 — intervention group
Group type: COMPARATOR
Intervention: Attentional control DVD condition focused on healthy aging
Number of subjects: 307
Study 26499146 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal chemotherapy with Lobaplatin (40 mg intraoperatively) followed by intravenous FOLFOX regimen
Number of subjects: 103